AIM: To observe the clinical efficacy and safety of phacoemulsification surgery combined with intravitreal injection of conbercept in cataract patients with DME. METHODS: This is a prospective clinical cohort study. Thirty-five cataract patients (49 eyes) with DME were divided into two groups. The observation group (23 eyes) underwent a cataract phacoemulsification surgery combined with intravitreal injection of conbercept 0.5 mg; the control group (26 eyes) underwent a cataract phacoemulsification surgery only. The visual acuity, central macular thickness (CMT), IOP, and anterior chamber flare were examined before surgery and 1 week and one month after surgery. RESULTS: The UCVA and BCVA in Log MAR in the observation group were lower than those in the control group at 1 week (p=0.032; p=0.041) and 1 month (p=0.035; p=0.039), respectively, after the surgery. The CMT of the observation group changed from 492.7 ± 32.2 μm before surgery to 341.6 ± 59.9 μm one week after surgery and 374.8 ± 48.3 μm one month after surgery. The CMT of control group increased after surgery. There was no significant difference in IOP and flare between the two groups at all following times. CONCLUSION: In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation.
AIM: To observe the clinical efficacy and safety of phacoemulsification surgery combined with intravitreal injection of conbercept in cataract patients with DME. METHODS: This is a prospective clinical cohort study. Thirty-five cataract patients (49 eyes) with DME were divided into two groups. The observation group (23 eyes) underwent a cataract phacoemulsification surgery combined with intravitreal injection of conbercept 0.5 mg; the control group (26 eyes) underwent a cataract phacoemulsification surgery only. The visual acuity, central macular thickness (CMT), IOP, and anterior chamber flare were examined before surgery and 1 week and one month after surgery. RESULTS: The UCVA and BCVA in Log MAR in the observation group were lower than those in the control group at 1 week (p=0.032; p=0.041) and 1 month (p=0.035; p=0.039), respectively, after the surgery. The CMT of the observation group changed from 492.7 ± 32.2 μm before surgery to 341.6 ± 59.9 μm one week after surgery and 374.8 ± 48.3 μm one month after surgery. The CMT of control group increased after surgery. There was no significant difference in IOP and flare between the two groups at all following times. CONCLUSION: In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation.
Authors: Carlo Cagini; Tito Fiore; Barbara Iaccheri; Francesco Piccinelli; Maria Antonietta Ricci; Daniela Fruttini Journal: Curr Eye Res Date: 2009-12 Impact factor: 2.424
Authors: Alastair K Denniston; Usha Chakravarthy; Haogang Zhu; Aaron Y Lee; David P Crabb; Adnan Tufail; Clare Bailey; Toks Akerele; Sahar Al-Husainy; Christopher Brand; Louise Downey; Alan Fitt; Rehna Khan; Vineeth Kumar; Aires Lobo; Sajjad Mahmood; Kaveri Mandal; Martin Mckibbin; Geeta Menon; Salim Natha; Jong Min Ong; Marie D Tsaloumas; Atul Varma; Elizabeth Wilkinson; Robert L Johnston; Catherine A Egan Journal: Br J Ophthalmol Date: 2017-05-09 Impact factor: 4.638